Royal Philips has received clearance from Japan’s healthcare authority to launch its Lumify with Reacts handheld tele-ultrasound solution in the country.

The solution allows quick and easy access to diagnostic ultrasound imaging. It enables clinicians to remotely collaborate with care professionals for bedside diagnosis and to monitor medical conditions.

Lumify’s tele-ultrasound capabilities can also be used in medical student and healthcare worker remote training programmes, the company noted.

Philips Access and Obstetric Ultrasound general manager Matthijs Wassink said: “By bringing diagnostic insight to the point of care, Lumify is a great example of how Philips is supporting providers to deliver on the ambition of the ‘quadruple aim’ in healthcare – better health outcomes, an improved experience for patients and staff and a lower cost of care.

“Its transducer connects to a smart device such as a tablet, making it a compact and highly durable solution. In addition, by using Philips’ Lumify with Reacts capability, real-time ultrasound images can be shared between medical staff involved in collaboration during imaging procedures.”

Philips noted that handheld and portable ultrasound solutions have become valuable tools for clinicians during Covid-19 pandemic because of their imaging capabilities, portability and ease of disinfection.

The company’s various ultrasound solutions are approved for the management of Covid-19-related lung and cardiac complications in markets such as Brazil, Australia, Canada, the EU, New Zealand and the US.

This includes ultrasound systems such as the EPIQ series, Affiniti series, Lumify, CX50 and Sparq diagnostic ultrasound systems and off-cart solutions, including QLAB Advanced Quantification Software.

Last month, Philips received 510(k) clearance from the US Food and Drug Administration (FDA) for its wearable biosensor to monitor Covid-19 patients in hospitals.